Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study Neumora Therapeutics, Inc. has initiated a Phase 1 clinical study of NMRA-898, a M4 positive allosteric modulator.
Kymera Therapeutics Presents New Preclinical Data for KT-579 Kymera Therapeutics, Inc. announced the presentation of new preclinical data …
CTD-ILD Burden on Older Patients and Women The incidence and prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-…
Swift Solar Deploys Perovskite Modules at DoD Cyber Exercise Swift Solar, a US solar technology company, has deployed perovskite solar tec…
South Africa Approves Lenacapavir for HIV Prevention South Africa's Health Product Regulatory Authority (SAHPRA) has approved lenacapavir,…
Lululemon to Sell NFL Apparel in Fanatics Deal Lululemon has entered an arrangement with the NFL and Fanatics to develop a line of fan app…
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial Zenas BioPharma, a clinical-stage global biopharmaceutical company…
Can the Warriors Maximize Stephen Curry's Remaining Years? Stephen Curry remains an exceptional player, and his supporting cast has improv…
New Parking Initiative to Boost Waverley Town Centres Waverley Borough Council is trialing a new parking scheme, "Pay One, Stay Two", to e…
Ericsson and Nokia Collaborate on 6G Video Research Nokia, Ericsson, and the Fraunhofer Heinrich Hertz Institute have presented a proof-of…
Utah's Olympic Organizers in NYC Leaders of Utah's 2034 Winter Games are attending the U.S. Olympic and Paralympic Committee Team USA Medi…